News
This drug led to 50% more weight loss than Wegovy in head-to-head study
While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors find concerning. In trials of Wegovy, up to 40% of weight loss was from a decrease in lean or fat-free mass, rather than excess fat. In addition, quitting the drugs can mean adding back the pounds.
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide,
Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...
Novo Nordisk A/S shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback